The ISN-ACT Clinical Trials Toolkit is an open-access, online resource to assist trial design, study conduct, data management, data analysis, and publication. More than ever, clinical trials in nephrology are needed to generate high-quality evidence to inform all aspects of care for patients with or at risk of kidney disease, including those affected by COVID-19. Access...
Every month the ISN-ACT Team lists interesting new randomized controlled trials from around the world. Highlight: Diltiazem may be superior to nifedipine for post-partum hypertension in pregnancy. See the latest trials here. From October 2020, the GTF will be available in French, Spanish, Arabic, and Mandarin. Would you like to support equal access to nephrology research? Become an ISN...
Dr. Rolando Claure Del Granado and colleagues involved in the ISN 0by25 initiative in Bolivia Every year, the Scientific Committee of the Medical College of Bolivia awards outstanding studies and investigators that significantly impact the local population. This year, the jury recognized the academic and research activities of Dr. Rolando Claure Del Granado and selected the...
The ISN-ACT Global Trials Focus team has collected and published a new list of randomized research from nephrologists around the world for August 2020. Each trial is reviewed in context and the risk of bias in seven key areas is assessed. Highlight: Allopurinol does not slow the progression of chronic kidney disease in patients with type 1...
The full DAPA-CKD trial results will be presented and reviewed at the ESC Congress 2020, Sunday, August 30, 17:00 – 17:30 CET. Topic Renal failure and Cardiovascular Disease Chairpersons Rory Collins (Oxford, UK); Frank Ruschitzka (Zurich, Switzerland) Presentations: DAPA-CKD – Dapagliflozin in Patients with CKD: Hiddo Heerspink (Groningen, Netherlands) DAPA- CKD – Live Prime Discussion: Diederick E Grobbee (Utrecht, Netherlands) Q&A Session The...
The ISN invites nephrologists to register patients affected by COVID-19 on the new global COVID registry. The ISN collaborated with the University of Cambridge to develop CORONATION, the Coronavirus multinational observational registry, a data entry portal accessible to nephrologists worldwide to collect anonymous data on individual people with kidney disease and the COVID-19 infection. For more information, please visit...
Kidney International will shortly publish the International Consensus Definitions of Clinical Trial Outcomes for Kidney Failure: 2020, developed from the 1st International Consensus Meeting on Defining Kidney Failure in Clinical Trials hosted by the ISN in Vancouver, BC, Canada, in early 2020. This is the first attempt by the international nephrology community to identify reproducible,...
Every month the ISN-ACT Team lists interesting new randomized controlled trials from around the world. Highlight: Early ACE-inhibition is safe in pediatric Alport’s Syndrome and may be effective See the latest trials here
The International Society of Nephrology urges all investigators and industry partners to include people with kidney diseases in research activities related to COVID-19. The ISN-ACT (Advancing Clinical Trials) Committee has released a statement on the urgent need to include patients with kidney diseases in clinical trials related to COVID-19. Despite preliminary studies demonstrating the increased risk...
Find key results from your region through scorecards. Available here Share the results from your region via social media or other media and press channels to support discussions on and advocate for kidney health care.
